From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Abstract mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in accordance with their superiority in expressing all sequence‐known proteins in vivo. In particular, with a small dosage of delivered mRNA, antigen‐presenting cells (APCs) can synthesize mutant neo‐antigens and mult...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Exploration |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/EXP.20210146 |
| _version_ | 1797202518604775424 |
|---|---|
| author | Feng Zhou Lujia Huang Shiqin Li Wenfang Yang Fangmin Chen Zhixiong Cai Xiaolong Liu Wujun Xu Vesa‐Pekka Lehto Ulrich Lächelt Rongqin Huang Yang Shi Twan Lammers Wei Tao Zhi Ping Xu Ernst Wagner Zhiai Xu Haijun Yu |
| author_facet | Feng Zhou Lujia Huang Shiqin Li Wenfang Yang Fangmin Chen Zhixiong Cai Xiaolong Liu Wujun Xu Vesa‐Pekka Lehto Ulrich Lächelt Rongqin Huang Yang Shi Twan Lammers Wei Tao Zhi Ping Xu Ernst Wagner Zhiai Xu Haijun Yu |
| author_sort | Feng Zhou |
| collection | DOAJ |
| description | Abstract mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in accordance with their superiority in expressing all sequence‐known proteins in vivo. In particular, with a small dosage of delivered mRNA, antigen‐presenting cells (APCs) can synthesize mutant neo‐antigens and multi‐antigens and present epitopes to T lymphocytes to elicit antitumor effects. In addition, expressing receptors like chimeric antigen receptor (CAR), T‐cell receptor (TCR), CD134, and immune‐modulating factors including cytokines, interferons, and antibodies in specific cells can enhance immunological response against tumors. With the maturation of in vitro transcription (IVT) technology, large‐scale and pure mRNA encoding specific proteins can be synthesized quickly. However, the clinical translation of mRNA‐based anticancer strategies is restricted by delivering mRNA into target organs or cells and the inadequate endosomal escape efficiency of mRNA. Recently, there have been some advances in mRNA‐based cancer immunotherapy, which can be roughly classified as modifications of the mRNA structure and the development of delivery systems, especially the lipid nanoparticle platforms. In this review, the latest strategies for overcoming the limitations of mRNA‐based cancer immunotherapies and the recent advances in delivering mRNA into specific organs and cells are summarized. Challenges and opportunities for clinical applications of mRNA‐based cancer immunotherapy are also discussed. |
| first_indexed | 2024-04-24T08:04:43Z |
| format | Article |
| id | doaj.art-34b48205a3e34f03bd0a9eda1f1da5e0 |
| institution | Directory Open Access Journal |
| issn | 2766-8509 2766-2098 |
| language | English |
| last_indexed | 2024-04-24T08:04:43Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Exploration |
| spelling | doaj.art-34b48205a3e34f03bd0a9eda1f1da5e02024-04-17T12:18:40ZengWileyExploration2766-85092766-20982024-04-0142n/an/a10.1002/EXP.20210146From structural design to delivery: mRNA therapeutics for cancer immunotherapyFeng Zhou0Lujia Huang1Shiqin Li2Wenfang Yang3Fangmin Chen4Zhixiong Cai5Xiaolong Liu6Wujun Xu7Vesa‐Pekka Lehto8Ulrich Lächelt9Rongqin Huang10Yang Shi11Twan Lammers12Wei Tao13Zhi Ping Xu14Ernst Wagner15Zhiai Xu16Haijun Yu17State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaState Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaState Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaState Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaState Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaDepartment of Applied Physics University of Eastern Finland Kuopio FinlandDepartment of Applied Physics University of Eastern Finland Kuopio FinlandDepartment of Pharmaceutical Sciences University of Vienna Vienna AustriaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery Ministry of Education, Fudan University Shanghai ChinaDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging RWTH Aachen University Clinic Aachen GermanyDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging RWTH Aachen University Clinic Aachen GermanyCenter for Nanomedicine and Department of Anaesthesiology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USAInstitute of Biomedical Health Technology and Engineering and Institute of Systems and Physical Biology Shenzhen Bay Laboratory Shenzhen ChinaPharmaceutical Biotechnology, Center for Nanoscience Ludwig‐Maximilians‐Universität Munich GermanySchool of Chemistry and Molecular Engineering East China Normal University Shanghai ChinaState Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaAbstract mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in accordance with their superiority in expressing all sequence‐known proteins in vivo. In particular, with a small dosage of delivered mRNA, antigen‐presenting cells (APCs) can synthesize mutant neo‐antigens and multi‐antigens and present epitopes to T lymphocytes to elicit antitumor effects. In addition, expressing receptors like chimeric antigen receptor (CAR), T‐cell receptor (TCR), CD134, and immune‐modulating factors including cytokines, interferons, and antibodies in specific cells can enhance immunological response against tumors. With the maturation of in vitro transcription (IVT) technology, large‐scale and pure mRNA encoding specific proteins can be synthesized quickly. However, the clinical translation of mRNA‐based anticancer strategies is restricted by delivering mRNA into target organs or cells and the inadequate endosomal escape efficiency of mRNA. Recently, there have been some advances in mRNA‐based cancer immunotherapy, which can be roughly classified as modifications of the mRNA structure and the development of delivery systems, especially the lipid nanoparticle platforms. In this review, the latest strategies for overcoming the limitations of mRNA‐based cancer immunotherapies and the recent advances in delivering mRNA into specific organs and cells are summarized. Challenges and opportunities for clinical applications of mRNA‐based cancer immunotherapy are also discussed.https://doi.org/10.1002/EXP.20210146cancer immunotherapycell‐targeted deliverymRNA designmRNA therapeuticsorgan‐specific delivery |
| spellingShingle | Feng Zhou Lujia Huang Shiqin Li Wenfang Yang Fangmin Chen Zhixiong Cai Xiaolong Liu Wujun Xu Vesa‐Pekka Lehto Ulrich Lächelt Rongqin Huang Yang Shi Twan Lammers Wei Tao Zhi Ping Xu Ernst Wagner Zhiai Xu Haijun Yu From structural design to delivery: mRNA therapeutics for cancer immunotherapy Exploration cancer immunotherapy cell‐targeted delivery mRNA design mRNA therapeutics organ‐specific delivery |
| title | From structural design to delivery: mRNA therapeutics for cancer immunotherapy |
| title_full | From structural design to delivery: mRNA therapeutics for cancer immunotherapy |
| title_fullStr | From structural design to delivery: mRNA therapeutics for cancer immunotherapy |
| title_full_unstemmed | From structural design to delivery: mRNA therapeutics for cancer immunotherapy |
| title_short | From structural design to delivery: mRNA therapeutics for cancer immunotherapy |
| title_sort | from structural design to delivery mrna therapeutics for cancer immunotherapy |
| topic | cancer immunotherapy cell‐targeted delivery mRNA design mRNA therapeutics organ‐specific delivery |
| url | https://doi.org/10.1002/EXP.20210146 |
| work_keys_str_mv | AT fengzhou fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT lujiahuang fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT shiqinli fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT wenfangyang fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT fangminchen fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT zhixiongcai fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT xiaolongliu fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT wujunxu fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT vesapekkalehto fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT ulrichlachelt fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT rongqinhuang fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT yangshi fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT twanlammers fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT weitao fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT zhipingxu fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT ernstwagner fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT zhiaixu fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy AT haijunyu fromstructuraldesigntodeliverymrnatherapeuticsforcancerimmunotherapy |